IPO Year: 2024
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $12.00 | Buy | H.C. Wainwright |
| 12/30/2024 | $20.00 | Buy | H.C. Wainwright |
| 8/13/2024 | $21.00 | Buy | Jefferies |
| 8/13/2024 | $23.00 | Overweight | Cantor Fitzgerald |
| 8/13/2024 | Buy | TD Cowen | |
| 8/13/2024 | $18.00 | Outperform | Wedbush |
| 8/13/2024 | $23.00 | Buy | Needham |
IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and
SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)